Ondansetron Eg

Ondansetron, the active ingredient in Ondansetron EG, is a 5‑HT3 receptor antagonist presented as oral tablets for oral use. It helps prevent nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative settings in adult patients.

GNH USA supplies Ondansetron EG as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron, a 5‑HT3 receptor antagonist, is used to manage nausea and vomiting related to specific medical interventions.

- Chemotherapy‑induced nausea and vomiting: prevents and treats nausea and vomiting in patients receiving cytotoxic chemotherapy. - Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. - Radiotherapy‑induced nausea and vomiting: helps control nausea and vomiting associated with radiation treatment.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements are reported. - Diarrhoea: occasional loose stools. - Fatigue: feelings of tiredness or weakness. - Dizziness: transient light‑headedness. - Abdominal pain: mild stomach discomfort.

Serious or Rare Side Effects: - Cardiac arrhythmia (QT prolongation): may lead to serious rhythm disturbances. - Severe allergic reaction (anaphylaxis): rapid onset of rash, swelling, or breathing difficulty. - Serotonin syndrome: rare but potentially life‑threatening when combined with other serotonergic agents. - Severe hypotension: sudden drop in blood pressure. - Hepatic dysfunction: abnormal liver enzyme elevations. - Neuroleptic malignant‑like syndrome: extremely rare neuromuscular complications.

Before initiating therapy, consider the following precautions.

- Cardiac assessment: evaluate QT interval and cardiac history. - Concomitant QT‑prolonging drugs: avoid or monitor use with other agents that lengthen QT. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia prior to treatment. - Hepatic impairment: use with caution; dose adjustment may be required. - Pregnancy and lactation: weigh potential benefits against limited safety data. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Ondansetron may interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Amiodarone: additive QT‑prolongation risk. - Cisapride: significant QT prolongation. - Quinidine: increased risk of cardiac arrhythmia. - Domperidone: combined effect on cardiac conduction. - Certain antipsychotics (e.g., haloperidol): heightened QT prolongation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Aprepitant: may require dose adjustment. - Dexamethasone: may increase ondansetron exposure. - Serotonergic agents (e.g., SSRIs): monitor for serotonin syndrome.